Urinary porphyrin excretion in hepatitis C infection

Clinical Chemistry and Laboratory Medicine

Volumn 37, Issue 8, 1999, Pages 799-804

  Vogeser, Michael ^a,b   Jacob, Karl ^a   Zachoval, Reinhart ^b  

^a Klin Chem Inst   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Chronic hepatic porphyria; Coproporphyrin isomers; Hepatitis C; Secondary porphyrinuria

Indexed keywords

ALBUMIN; BILIRUBIN; COPROPORPHYRIN; CREATININE; HEME; PORPHYRIN; UROPORPHYRIN;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GERMANY; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; METABOLISM; PORPHYRIA CUTANEA TARDA; PORPHYRIN METABOLISM; PRIORITY JOURNAL; THROMBIN TIME; URINARY EXCRETION;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PORPHYRINS; PROSPECTIVE STUDIES;

HEPATITIS C VIRUS;

EID: 0032864035     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1999.120     Document Type: Article

References (41)

1. Fargion S, Piperno A, Cappellini MD, Sampietro M, Francanzani AL, Romano R, et al. Hepatitis C virus and porphyria cutanea tarda; evidence of a strong association. Hepatology 1992; 16:1322-6.
2. Navas S, Bosch O, Castillo I, Marriott E, Carreno V. Porphyria cutanea tarda and hepatitis C and B virus infection: a retrospective study. Hepatology 1995; 21:279-84.
3. Stoelzel U, Koestler E, Koszka C, Stoeffler-Meilicke M, Schuppan D, Somasundaram R, et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 1995: 21:1500-3.
4. Lamoril J, Andant C, Bogard C, Puy H, Gouya L, Pawlotsky JM, et al. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology 1998; 27:848-52.
5. Aziz MA, Schwartz S, Watson CJ. Studies of coproporphyrin. VIII. Reinvestigation of the isomer distribution in jaundice and liver diseases. J Lab Clin Med 1964; 63:596-604.
6. Doss M. Pathobiochemical transition of secondary coproporphyrinuria to chronic hepatic porphyria in humans. Klin Wochenschr 1980; 58:141-8.
7. Grossman ME, Bickers DR, Poh-Fitzpatrick MB, Deleo VA, Harber LC. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. Am J Med 1979; 67:277-86.
8. Bengtsson NO, Hardell L. Porphyrias, porphyrins and hepatocellular cancer. Br J Cancer 1986; 54:115-7.
9. Batlle A. Porphyrins, porphyrias, cancer and photodynamic therapy - a model for carcinogenesis. J Photochem Photobiol 1993; 20:5-22.
10. Salata H, Cortes JM, de Salamanca RE, Oliva H, Castro A, Kusak E, et al. Porphyria cutanea tarda and hepatocellular cancer. Frequency of occurrence and related factors. J Hepatol 1985, 5:477-87.
11. Siersema PD, ten Kate FJW, Mulder PGH, Wilson JHP. Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver 1992; 12:56-61.
12. Lithner F, Wetterberg L. Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta Med Scand 1984; 215:271-4.
13. Kauppinen R, Mustajoki P. Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer 1988; 57:117-20.
14. Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med 1996; 240:195-201.
15. Andant C, Puy H, Deybach JC, Soule JC, Nordmann Y. Occurrence of hepatocellular carcinoma in a case of hereditary coproporphyria. Am J Gastroenterol 1997; 92:1389-99.
16. Udagawa M, Horie Y, Hirayama C. Aberrant porphyrin metabolism in hepatocellular carcinoma. Biochem Med 1984; 31:131-9.
17. Tio TH, Leijnse B, Jarrett A, Rimington C. Acquired porphyria from a liver tumour. Clin Sci 1957; 16:517-24.
18. Ochiai T, Morishima T, Kondo M. Symptomatic porphyria secondary to hepatocellular carcinoma. Br J Dermatol 1997; 136:129-31.
19. Hurst EW, Paget GE. Protoporphyrin, cirrhosis and hepatomata in the livers of mice given griseofulvin. Br J Dermatol 1963; 75:105-12.
20. Silbergeld EK, Fowler BA. Porphyrins as indicators of chemical injury and exposure. Ann NY Ac Sci 1987; 514:170-1.
21. Smith AG, Carthew P, Francis JE, Ingebrigtsen K. Influence of iron on the induction of hepatic tumors and porphyria by octachlorostyrene in C57BL/10ScSn mice. Cancer Lett 1994; 81:145-50.
22. Batlle A, Riley PA. Abnormality of heme synthesis as the initial lesion in carcinogenesis. Cancer J 1991; 4:326-31.
23. Stout DL, Becker FF. Heme enzyme patterns in rat liver nodules and tumors. Cancer Res 1987; 15:963-6.
24. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26 (Suppl 1):S34-8.
25. Ostrowski J, Kosecki P, Martynska M, Milewski B. Urinary porphyrins in liver disease. Scand J Gastroenterol 1984; 19:862-6.
26. Cribier B, Rey D, Uhl G, Le Coz C, Hirth C, Libbrecht E, et al. Abnormal urinary coproporphyrin levels in patients infected by hepatitis C virus with or without human immunodeficiency virus. Arch Dermatol 1996; 132:1448-52.
27. O'Reilly FM, Darby C, Fogarty J, O'Moore R, Courtney MG, O'Connor J, et al. Porphyrin metabolism in hepatitis C infection. Photodermatol Photoimmunol Photomed 1996; 12:31-3.
28. Gomi H, Hatanaka K, Miura T, Matsuo I. Type of impaired porphyrin metabolism caused by hepatitis C virus is not porphyria cutanea tarda but chronic hepatic porphyria. Arch Dermatol 1997; 133:1170-1.
29. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27:1661-9.
30. Jacob K, Luppa P. Application of ion pair high performance liquid chromatography to the analysis of porphyrins in clinical samples. Biomed Chromatogr 1991; 5:122-7.
31. Kodama T, Kondo M, Urata G, Satoh H, Ohtake H, Iwasaki Y, et al. Changes in aminolevulinate synthase and aminolevulinate dehydratase activity in cirrhotic liver. Gastroenterology 1983; 84:236-41.
32. Kaczynski J, Hansson G, Thunell S, Wetterberg L, Wallerstedt S. Erythrocyte porphobilinogen deaminase activity and primary liver cancer. J Intern Med 1995; 237:309-13.
33. Doss M, Look D, Henning H, Nawrocki P, Schmidt A, Doelle W, et al. Hepatic porphyrins and urinary porphyrins and porphyrin precursors in liver cirrhosis. Klin Wochenschr 1972; 50: 1025-32.
34. Moran MJ, Fontanellas A, Brudieux E, Hombrados I, De Ledinghen V, Couzigou P, et al. Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus C infection. Hepatology 1998; 27:584-9.
35. Francis JE, Smith AG. Oxidation of uroporphyrinogens by hydroxyl radicals. Evidence for nonporphyrin products as potential inhibitors of uroporphyrinogen decarboxylase. FEBS Let 1988; 233:311-4.
36. El-Sharabasy MMH, El-Waseef AM, Hafez MM, Salim SA. Porphyrin metabolism in some malignant diseases. Br J Cancer 1992; 65:409-12.
37. O'Connor WJ, Murphy GM, Darby C, Fogarty J, Mulcahy F, O'Moore RC, et al. Porphyrin abnormalities in acquired immunodeficiency syndrome. Arch Dermatol 1996; 32:1443-7.
38. Riggio O, Montagnese F, Fiore P, Folino S, Giambartolomei S, Gandin C, et al. Iron overload in patients with chronic viral hepatitis. How common is it? Am J Gastroenterol 1997; 92:1298-301.
39. Rsai NC, Zuckerman E, Han SH, Goad K, Redecker AG, Fong TI. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterology 1997; 92:1831-4.
40. O'Reilly FM, Darby C, Fogarty J, Tormey W, Kay EW, Path MRC, et al. Screening of patients with iron overload to identify hemochromatosis and porphyria cutanea tarda. Arch Dermatol 1997; 133:1098-101.
41. Stuart KA, Busfield F, Jazwinska C, Gibson P, Butterworth LA, Cooksley WG, et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 1998; 28:404-9.